Natalie Gauci
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Natalie Gauci has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Alison Poulton
Nepean Clinical School, The University of Sydney, Sydney Australia
2 shared publications- Alison Poulton
Department of Paediatrics Nepean Hospital Penrith New South Wales Australia
2 shared publications Emily Hibbert
Nepean Clinical School, The University of Sydney, Sydney Australia
2 shared publications- Emily Jane Hibbert
Nepean Clinical School, Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia
2 shared publications Hazer Khalifa
Nepean Clinical School, The University of Sydney, Sydney Australia
2 shared publications- Hazer Khalifa
Nepean Clinical School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2050, Australia
2 shared publications
Latest Publications
- Open Access
- 3 February 2025
- Published by MDPI AG in Psychoactives
- Vol. 4 (1) , 3
Does Dexamphetamine Cause Addiction? A Narrative Review
Dexamphetamine (DEX) is widely used in treatments, but concerns persist about its potential for addiction. This review aimed to assess the risks of DEX addiction by examining the existing literature. Originally planned as a systematic review, it was adjusted to a narrative review due to a lack of qualifying studies. A search of the literature on addiction to DEX was conducted on three databases including PubMed, Scopus, and Embase. Seven articles consisting of three reviews and four papers with original data were identified and reviewed. In total, four poorly documented cases of possible DEX addiction were found. The commonly cited papers on prescription DEX addiction did not hold up to scrutiny. Overall, the evidence that DEX is addictive is limited and inconclusive, highlighting the need for more rigorous research to clarify its true addiction risk.
- 3 February 2025
- Published by MDPI AG in Psychoactives
- Vol. 4 (1) , 3
Open AccessDoes Dexamphetamine Cause Addiction? A Narrative Review
Dexamphetamine (DEX) is widely used in treatments, but concerns persist about its potential for addiction. This review aimed to assess the risks of DEX addiction by examining the existing literature. Originally planned as a systematic review, it was adjusted to a narrative review due to a lack of qualifying studies. A search of the literature on addiction to DEX was conducted on three databases including PubMed, Scopus, and Embase. Seven articles consisting of three reviews and four papers with original data were identified and reviewed. In total, four poorly documented cases of possible DEX addiction were found. The commonly cited papers on prescription DEX addiction did not hold up to scrutiny. Overall, the evidence that DEX is addictive is limited and inconclusive, highlighting the need for more rigorous research to clarify its true addiction risk.
- Open Access
- 18 December 2024
- Published by MDPI AG in Brain Sciences
- Vol. 14 (12) , 1274
The Impact of Dexamphetamine Treatment for Obesity on Executive Function: A Double-Blind Randomised Controlled Pilot Study
Background: Amphetamines increase dopamine levels in mid-brain regions which, in turn, impact top-down executive function. Repeated exposure is linked to substance use disorders. Nonetheless, amphetamines are used to manage attention-deficit/hyperactivity disorder (ADHD) and eating-related disorders. In ADHD, amphetamines upregulate a system characterised by low dopaminergic tone, assisting to improve executive function. A similar process might be at play with eating disorders; however, the effect of amphetamine treatment on executive function in this case has not been thoroughly considered. Methods: Participants (N = 52, Mage = 47.06, SD = 12.29) with a body mass index of 25–60 were randomised to treatment (6-week dexamphetamine titration) or control (placebo) groups. They completed an executive function measure—Barkley Deficits in Executive Functioning Scale (BDEFS-SF)—and response inhibition task—Stop-Signal Task (SST)—at Baseline, throughout titration, at Maintenance, and at Follow-up. Mixed effects models examined whether BDEFS-SF score or the SST variable, stop-signal reaction time (SSRT), changed across sessions as a function of treatment. Results: There was no effect of group (p = 0.440), but an effect of session (p = 0.024) on BDEFS-SF, with scores at Time 2 (p = 0.011, 95% CI [0.47, 3.49]) and Maintenance (p = 0.022, 95% CI [−4.89, −0.39]), respectively, higher and lower than other timepoints. There was no group by session interaction (p = 0.659). R2 (conditional) = 0.74; ICC = 0.73. There was an effect of group (p = 0.039) and session (p < 0.001) on SSRT, but no interaction (p = 0.707). Baseline SSRT was significantly longer than the mean of all subsequent timepoints (p < 0.001, 95% CI [16.29, 33.84]). R2 (conditional) = 0.47; ICC = 0.39. Conclusions: There was no discernible impact of amphetamine treatment for obesity on executive function. Our results suggest some variation related to sample size and/or practice effects. Thus, while treatment appears unlikely to render individuals susceptible to substance use disorders, parallels with ADHD might be overstated.
- 18 December 2024
- Published by MDPI AG in Brain Sciences
- Vol. 14 (12) , 1274
Open AccessThe Impact of Dexamphetamine Treatment for Obesity on Executive Function: A Double-Blind Randomised Controlled Pilot Study
Background: Amphetamines increase dopamine levels in mid-brain regions which, in turn, impact top-down executive function. Repeated exposure is linked to substance use disorders. Nonetheless, amphetamines are used to manage attention-deficit/hyperactivity disorder (ADHD) and eating-related disorders. In ADHD, amphetamines upregulate a system characterised by low dopaminergic tone, assisting to improve executive function. A similar process might be at play with eating disorders; however, the effect of amphetamine treatment on executive function in this case has not been thoroughly considered. Methods: Participants (N = 52, Mage = 47.06, SD = 12.29) with a body mass index of 25–60 were randomised to treatment (6-week dexamphetamine titration) or control (placebo) groups. They completed an executive function measure—Barkley Deficits in Executive Functioning Scale (BDEFS-SF)—and response inhibition task—Stop-Signal Task (SST)—at Baseline, throughout titration, at Maintenance, and at Follow-up. Mixed effects models examined whether BDEFS-SF score or the SST variable, stop-signal reaction time (SSRT), changed across sessions as a function of treatment. Results: There was no effect of group (p = 0.440), but an effect of session (p = 0.024) on BDEFS-SF, with scores at Time 2 (p = 0.011, 95% CI [0.47, 3.49]) and Maintenance (p = 0.022, 95% CI [−4.89, −0.39]), respectively, higher and lower than other timepoints. There was no group by session interaction (p = 0.659). R2 (conditional) = 0.74; ICC = 0.73. There was an effect of group (p = 0.039) and session (p < 0.001) on SSRT, but no interaction (p = 0.707). Baseline SSRT was significantly longer than the mean of all subsequent timepoints (p < 0.001, 95% CI [16.29, 33.84]). R2 (conditional) = 0.47; ICC = 0.39. Conclusions: There was no discernible impact of amphetamine treatment for obesity on executive function. Our results suggest some variation related to sample size and/or practice effects. Thus, while treatment appears unlikely to render individuals susceptible to substance use disorders, parallels with ADHD might be overstated.
- 9 September 2023
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 62 (suppl 67) , PA3591
Two birds, one stone: a RCT investigating the efficacy of dexamfetamine for treating obesity and obstructive sleep apnoea
Background: Weight loss is often prescribed for patients with Obstructive Sleep Apnoea (OSA) to aid in reducing the severity of the disorder. However, most weight loss attempts are unsuccessful without professional supervision. Anti-obesity medications can be expensive, and cheaper medications are required. Dexamfetamine (DEX), could be a suitable alternative. The aim of this study is to test whether a 6 month treatment of DEX is more effective than placebo in treating obesity and reducing the severity of OSA. Methods: Double blind randomised placebo-controlled trial of 6 months treatment followed by 2 years observation, with 2 groups of 30 participants per group. Participants are randomised 1:1 to either immediate release DEX tablets or identical placebo tablets. The dose is titrated to a maximum of 30mg/6 tablets twice daily. Each participant is reviewed weekly during titration followed by monthly review at maintenance. Dosage adjustment is guided by clinical effects and ratings using the amphetamine interview rating scale. Overnight sleep study is performed pre and post treatment. Results: The data remains blinded and is the combination of DEX and placebo groups. 52 subjects have been consented into the study (33 male, mean age 47 years). Mean weight loss at 6 months was 9.04 kg (95% CI 6.29 – 11.77, p<0.001). Mean reduction in AHI was 7.81 (95% Cl -1.81 – 17.44, p=0.108). Mean reduction in oxygen desaturation index (ODI) was 12.85 (95% Cl 1.34 – 24.35, p=0.030). Conclusions: The preliminary results suggest DEX may be a cheaper alternative to newer appetite supression drugs and merits further research.
- 9 September 2023
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 62 (suppl 67) , PA3591
Two birds, one stone: a RCT investigating the efficacy of dexamfetamine for treating obesity and obstructive sleep apnoea
Background: Weight loss is often prescribed for patients with Obstructive Sleep Apnoea (OSA) to aid in reducing the severity of the disorder. However, most weight loss attempts are unsuccessful without professional supervision. Anti-obesity medications can be expensive, and cheaper medications are required. Dexamfetamine (DEX), could be a suitable alternative. The aim of this study is to test whether a 6 month treatment of DEX is more effective than placebo in treating obesity and reducing the severity of OSA. Methods: Double blind randomised placebo-controlled trial of 6 months treatment followed by 2 years observation, with 2 groups of 30 participants per group. Participants are randomised 1:1 to either immediate release DEX tablets or identical placebo tablets. The dose is titrated to a maximum of 30mg/6 tablets twice daily. Each participant is reviewed weekly during titration followed by monthly review at maintenance. Dosage adjustment is guided by clinical effects and ratings using the amphetamine interview rating scale. Overnight sleep study is performed pre and post treatment. Results: The data remains blinded and is the combination of DEX and placebo groups. 52 subjects have been consented into the study (33 male, mean age 47 years). Mean weight loss at 6 months was 9.04 kg (95% CI 6.29 – 11.77, p<0.001). Mean reduction in AHI was 7.81 (95% Cl -1.81 – 17.44, p=0.108). Mean reduction in oxygen desaturation index (ODI) was 12.85 (95% Cl 1.34 – 24.35, p=0.030). Conclusions: The preliminary results suggest DEX may be a cheaper alternative to newer appetite supression drugs and merits further research.